22 results
8-K
EX-99.2
TFX
Teleflex Incorporated
24 Feb 22
Teleflex Announces Fourth Quarter and Full-Year 2021 Financial Results
7:00am
Interventional: Expanded Indication for CTO-PCI FDA 510(k) clearance received for use of specialty catheters and guidewires(1) in chronic total occlusions (CTOs
8-K
EX-99.2
TFX
Teleflex Incorporated
25 Feb 21
Teleflex Reports Fourth Quarter and Full Year 2020 Results; Provides 2021 Guidance
7:00am
catheters in Chronic Total Occlusion (CTO) percutaneous coronary intervention (PCI) procedures ◦ Study devices included GuideLiner® V3 catheter, TrapLiner®
8-K
EX-99.2
TFX
Teleflex Incorporated
30 Jul 20
Teleflex Reports Second Quarter 2020 Results
7:09am
targeting 150 patients across ~15 US sites, to evaluate the performance of Teleflex coronary guidewires and specialty catheters in Chronic Total Occlusion
8-K
EX-99.2
tp9x9
11 May 18
Regulation FD Disclosure
9:09am
8-K
EX-99.2
kc9q0s04q u6s6be7
13 Dec 12
Regulation FD Disclosure
12:00am
424B2
nu68c6en9
10 Jun 11
Prospectus for primary offering
12:00am
424B2
ghz174jfrfeluh
1 Jun 11
Prospectus for primary offering
12:00am
8-K
EX-99.1
u18m2b6tcta9951m64o
1 Jun 11
Information Concerning Forward-Looking Statements
12:00am
8-K
EX-99.1
bmgk7yh
26 Apr 11
Regulation FD Disclosure
12:00am
8-K
EX-99.1
k058sa3tv
27 Jul 10
Information Concerning Forward-Looking Statements
12:00am